Profile
Christopher Benecchi is Chief Operating Officer at Inventiva SA since 2026.
Formerly, Mr. Benecchi was Chief Executive Officer at Motric Bio, Inc. Mr. Benecchi was Vice President & Global Head-Commercial Excellence at Alexion Pharmaceuticals, Inc. from 2019 to 2021.
Mr. Benecchi was Global Launch Head-Commercial & Medical Affairs at UCB, Inc. from 2018 to 2019.
Mr. Benecchi was COO, Principal Financial & Accounting Officer at SAGE Therapeutics, Inc. from 2024 to 2025.
Mr. Benecchi earned an MBA from Duke University and completed undergraduate studies at Colby College.
Christopher Benecchi active positions
| Companies | Position | Start |
|---|---|---|
| INVENTIVA | Chief Operating Officer | 2026-08-30 |
Former positions of Christopher Benecchi
| Companies | Position | End |
|---|---|---|
| SAGE THERAPEUTICS, INC. | Director of Finance/CFO | 2025-07-31 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2021-08-31 |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Provides financial services | Corporate Officer/Principal | 2019-07-31 |
Education of Christopher Benecchi
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Duke University
Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Colby College
Colby College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
UCB, Inc.
UCB, Inc. Financial ConglomeratesFinance Provides financial services | Finance |
SAGE Therapeutics, Inc.
SAGE Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel medicines for central nervous system disorders | Health Technology |
Inventiva SA
Inventiva SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops oral small molecule therapies for the treatment of MASH and other diseases | Health Technology |
- Stock Market
- Insiders
- Christopher Benecchi
















